{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:07:34Z","timestamp":1788314854705,"version":"build-2803163510"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004442","name":"Narodowym Centrum Nauki","doi-asserted-by":"publisher","award":["2018\/30\/E\/NZ5\/00104, 2015\/16\/S\/NZ6\/00041, 2020\/04\/X\/N25\/01820"],"award-info":[{"award-number":["2018\/30\/E\/NZ5\/00104, 2015\/16\/S\/NZ6\/00041, 2020\/04\/X\/N25\/01820"]}],"id":[{"id":"10.13039\/501100004442","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>A number of studies have demonstrated a key role of miRNA isolated from cells, tissue or body fluids as disease-specific biomarkers of autoimmune rheumatic diseases including rheumatoid arthritis (RA) and systemic sclerosis (SSc). Also, the expression level of miRNA is changing during disease development, therefore miRNA can be used as biomarkers monitoring RA progression and treatment response. In this study we have investigated the monocytes-specific miRNA that could serve as potential biomarkers of disease progression observed in sera and synovial fluids (SF) in early (eRA) and advanced (aRA) RA and in RA patients before and 3 months after selective JAK inhibitor (JAKi) -baricitinib treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Samples from healthy control (HC) (n=37), RA (n=44) and SSc (n=10) patients were used. MiRNA-seq of HC, RA, and SSc monocytes was performed to find versatile miRNA present in different rheumatic diseases. Selected miRNAs were validated in body fluids in eRA (&amp;lt;2 years disease onset) and aRA (&amp;gt;2 years disease onset) and RA patients receiving baricitinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Using miRNA-seq, we selected top 6 miRNA out of 95 that were significantly changed in both RA and SSc monocytes compared to HC. To identify circulating miRNA predicting RA progression, these 6 miRNA were measured in eRA and aRA sera and SF. Interestingly, miRNA (-19b-3p, -374a-5p, -3614-5p) were significantly increased in eRA sera vs HC and even further upregulated in SF vs aRA sera. In contrast, miRNA-29c-5p was significantly reduced in eRA sera vs HC and even further decreased in SF vs aRA sera. Kegg pathway analysis predicted that miRNA were involved in inflammatory-mediated pathways. ROC analysis demonstrated that miRNA-19b-3p (AUC=0.85, p=0.04) can be used as biomarker predicting JAKi response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>In conclusion, we identified and validated miRNA candidates which were present simultaneously in monocytes, sera, SF and that can be used as biomarkers predicting joint inflammation and monitoring therapy response to JAKi in RA patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2023.980247","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T01:41:40Z","timestamp":1679967700000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Circulating miRNA-19b as a biomarker of disease progression and treatment response to baricitinib in rheumatoid arthritis patients through miRNA profiling of monocytes"],"prefix":"10.3389","volume":"14","author":[{"given":"Marzena","family":"Ciechomska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leszek","family":"Roszkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Burakowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Massalska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Felis-Giemza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adria-Jaume","family":"Roura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"100129","DOI":"10.1016\/j.jtauto.2021.100129","article-title":"Autoimmune rheumatic diseases: One or many diseases","volume":"4","author":"Moutsopoulos","year":"2021","journal-title":"J Transl Autoimmun"},{"key":"B2","article-title":"Pulmonary manifestations of systemic autoimmune diseases","volume":"6","author":"Cojocaru","year":"2011","journal-title":"Maedica (Bucur)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/35.4.364","article-title":"Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial","volume":"35","author":"van den Hoogen","year":"1996","journal-title":"Br J Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.semarthrit.2012.01.003","article-title":"Treatment of systemic sclerosis complications: what to use when first-line treatment fails\u2013a consensus of systemic sclerosis experts","volume":"42","author":"Walker","year":"2012","journal-title":"Semin Arthritis Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells10081860","article-title":"Tuning monocytes and macrophages for personalized therapy and diagnostic challenge in rheumatoid arthritis","volume":"10","author":"Roszkowski","year":"2021","journal-title":"Cells"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1614915","article-title":"Pathophysiology of systemic sclerosis: current understanding and new insights","volume":"15","author":"Cutolo","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab407","article-title":"MiR-29a reduces TIMP-1 production by dermal fibroblasts via targeting TGF-beta activated kinase 1 binding protein 1, implications for systemic sclerosis","volume":"9","author":"Ciechomska","year":"2014","journal-title":"PloS One"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201948428","article-title":"Global miRNA and mRNA expression profiles identify miRNA-26a-2-3p-dependent repression of IFN signature in systemic sclerosis human monocytes","volume":"50","author":"Ciechomska","year":"2020","journal-title":"Eur J Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab407","article-title":"Comprehensive microRNA and transcriptomic profiling of rheumatoid arthritis monocytes: role of microRNA-146b in pro-inflammatory progression","volume":"60","author":"Ciechomska","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/eci.12776","article-title":"The role of microRNA-5196 in the pathogenesis of systemic sclerosis","volume":"47","author":"Ciechomska","year":"2017","journal-title":"Eur J Clin Invest"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American college of Rheumatology\/European league against rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 Classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"105680","DOI":"10.1016\/j.phrs.2021.105680","article-title":"The emerging roles of exosomes in autoimmune diseases, with special emphasis on microRNAs in exosomes","volume":"169","author":"Miao","year":"2021","journal-title":"Pharmacol Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm9010161","article-title":"The serum cell-free microRNA expression profile in MCTD, SLE, SSc, and RA patients","volume":"9","author":"Stypinska","year":"2020","journal-title":"J Clin Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e111266","DOI":"10.1371\/journal.pone.0111266","article-title":"MiR-30a-3p negatively regulates BAFF synthesis in systemic sclerosis and rheumatoid arthritis fibroblasts","volume":"9","author":"Alsaleh","year":"2014","journal-title":"PloS One"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00005-018-0513-y","article-title":"Changes in MiRNA-5196 expression as a potential biomarker of anti-TNF-alpha therapy in rheumatoid arthritis and ankylosing spondylitis patients","volume":"66","author":"Ciechomska","year":"2018","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1038\/s41598-020-58506-5","article-title":"Assessing diagnostic value of microRNAs from peripheral blood mononuclear cells and extracellular vesicles in myalgic Encephalomyelitis\/Chronic fatigue syndrome","volume":"10","author":"Almenar-Perez","year":"2020","journal-title":"Sci Rep"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/diagnostics12020239","article-title":"Exploration of exosomal miRNAs from serum and synovial fluid in arthritis patients","volume":"12","author":"Xie","year":"2022","journal-title":"Diagn (Basel)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.7754\/Clin.Lab.2019.190139","article-title":"Clinical diagnosis value of miR-29b-3p in peripheral blood mononuclear cells and synovial fluid among osteoarthritis patients","volume":"65","author":"Chen","year":"2019","journal-title":"Clin Lab"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw116","article-title":"Distribution of miRNA expression across human tissues","volume":"44","author":"Ludwig","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1010428318775864","DOI":"10.1177\/1010428318775864","article-title":"microRNA expression in tumour tissue and plasma in patients with newly diagnosed metastatic prostate cancer","volume":"40","author":"Zedan","year":"2018","journal-title":"Tumour Biol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e0158946","DOI":"10.1371\/journal.pone.0158946","article-title":"Identification of specific miRNA signature in paired sera and tissue samples of Indian women with triple negative breast cancer","volume":"11","author":"Thakur","year":"2016","journal-title":"PloS One"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkr254","article-title":"Characterization of extracellular circulating microRNA","volume":"39","author":"Turchinovich","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00127","article-title":"Macrophage clearance of apoptotic cells: A critical assessment","volume":"9","author":"Gordon","year":"2018","journal-title":"Front Immunol"},{"key":"B25","article-title":"Combination of circulating miR-19b-3p, miR-122-5p and miR-486-5p expressions correlates with risk and disease severity of knee osteoarthritis","volume":"9","author":"Kong","year":"2017","journal-title":"Am J Transl Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1102348","article-title":"TLR2 expression is regulated by microRNA miR-19 in rheumatoid fibroblast-like synoviocytes","volume":"188","author":"Philippe","year":"2012","journal-title":"J Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s12974-020-01958-3","article-title":"Decreased expression of miR-29 family associated with autoimmune myasthenia gravis","volume":"17","author":"Cron","year":"2020","journal-title":"J Neuroinflammation"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2016.04.019","article-title":"Identification of synovial fluid microRNA signature in knee osteoarthritis: differentiating early- and late-stage knee osteoarthritis","volume":"24","author":"Li","year":"2016","journal-title":"Osteoarthritis Cartilage"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.18632\/aging.103855","article-title":"Extracellular-vesicle containing miRNA-503-5p released by macrophages contributes to atherosclerosis","volume":"13","author":"Wang","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"42899","DOI":"10.1038\/srep42899","article-title":"Integration of microRNA and mRNA expression profiles in the skin of systemic sclerosis patients","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci Rep"},{"key":"B31","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/jcmm.12754","article-title":"MicroRNA-503 promotes angiotensin II-induced cardiac fibrosis by targeting apelin-13","volume":"20","author":"Zhou","year":"2016","journal-title":"J Cell Mol Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.intimp.2018.07.028","article-title":"Analysis of miRNA expression in patients with rheumatoid arthritis during remission and relapse after a 5-year trial of tofacitinib treatment","volume":"63","author":"Fernandez-Ruiz","year":"2018","journal-title":"Int Immunopharmacol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.980247\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T01:41:45Z","timestamp":1679967705000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.980247\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,28]]},"references-count":32,"alternative-id":["10.3389\/fimmu.2023.980247"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.980247","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,28]]},"article-number":"980247"}}